OIG and CME: No Easy Answers

FOR THOSE OF YOU waiting for a list of do's and don'ts from the Office of Inspector General in order to help you comply with the OIG's new pharmaceutical marketing guidance and avoid violating federal anti-kickback laws, don't hold your breath.

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.